- 16Volume 3, 2020Jun 02, Issue 11May 19, Issue 10May 05, Issue 9Mar 10, Issue 5Feb 25, Issue 4Feb 04, Issue 3Jan 21, Issue 2Jan 07, Issue 01
- 15Volume 2, 2019Dec 17, Issue 22Nov 12, Issue 20Oct 28, Issue 19Oct 15, Issue 18Sep 03, Issue 15Aug 21, Issue 14Aug 05, Issue 13Jul 22, Issue 12Jul 08, Issue 11Jun 03, Issue 9May 13, Issue 8Apr 22, Issue 7Mar 11, Issue 4Feb 04, Issue 2Jan 21, Issue 1
- 14Volume 1, 2018Dec 21, Issue 12Dec 03, Issue 11Nov 19, Issue 10Nov 05, Issue 9Oct 22, Issue 8Oct 09, Issue 7Sep 24, Issue 6Sep 10, Issue 5Aug 15, Issue 4Jul 15, Issue 3Jul 01, Issue 1
Agenus on Twitter
FDA clears IND application for natural killer T-cell therapy @Agenus_Bio @Agentus_CellTX to treat #COVID19 - phase 1 trial to come bit.ly/2Ax2Rwscome bit.ly/2 Retweeted by Agenus Inc. ($AGEN)
FBR has informed callers to use 973-413-6102 twitter.com/Agenus_Bio/sta…
EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration pic.twitter.com/omgnBDFffg
— Agenus Inc. ($AGEN) (@Agenus_Bio) June 2, 2020
EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408. Retweeted by Agenus Inc. ($AGEN)
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients investor.agenusbio.com/2020-06-02-FDA… #COVID19 #immunology
Proud to be leading the charge with @Agenus_Bio and my oncology colleagues with a next generation CTLA-4 antibody. twitter.com/jbuell01/statu… Retweeted by Agenus Inc. ($AGEN)
ASCO Presentation of Agenus' AGEN1181 by Dr. Steven O'Day investor.agenusbio.com/2020-05-29-ASC… #ASCO2020
$AGEN sends special thanks to our AGEN1181 PIs & staff for your excellent care & continued accrual during this difficult #COVID19 pandemic: Dr. @ODayMD @JohnWayneCI; Dr El-Khouiery @USC; Dr. Gordon @HonorHealth; Dr. Bullock @BIDMChealth; Dr. Ramamurthy @UTHealthcareSA #ASCO2020
Agenus NEWSLETTER: Paulo Moriera leads path-breakers: advancing 14 new discoveries to clinic with FIM 2.5x faster than industry & readiness for 2 planned BLA filings in 2020. READ MORE: agenusbio.com/wp-content/upl…
@beilis_jay @jbuell01 The replay will also be available on our website after the discussion: investor.agenusbio.com/presentation-w…
@beilis_jay @jbuell01 rbccm.com/en/conference/… Access may be subject to registered attendees.
Join @Agenus_Bio at #RBCHealthcare2020 at 1:20PM when our President & COO Dr. Jennifer Buell (@jbuell01) will meet with Biotech Analyst Dr. Gregory Renza on Beyond 2020: The Changing Face of Healthcare.
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy - May 13, 2020 investor.agenusbio.com/2020-05-13-FDA…
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
Agenus First Quarter Update: AGEN1181+/- bali (PD-1) benefits 70% in P1; Bali/Zali combo shows 26% ORR (n=55); Two INDs filed for allogeneic iNKTs in cancer & COVID-19; Two TIGITs advancing to IND; structured to reduce burn ~$50 investor.agenusbio.com/2020-05-07-Age…
$AGEN Fc enhanced #TIGIT outperforms tested competitors (#AACR2019) & novel TIGIT bispecific shows potent tumor killing in difficult to treat CRC model. Both headed to clinic 1H21. #Immunotherapy agenusbio.com/wp-content/upl… Retweeted by Agenus Inc. ($AGEN)
NEWSLETTER: Two $AGEN TIGIT antibodies on track to enter clinic in 1H 2021. READ MORE: agenusbio.com/wp-content/upl…
$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.
.@armish, together we are a formidable force. twitter.com/armish/status/…
BTW, did I mention that I took a new job @Agenus_Bio?
— B. Arman Aksoy (@armish) April 30, 2020
With regards,
-- Recovering academic pic.twitter.com/Q6cXdoU3C7
$AGEN NEXT NEWSLETTER (May 5) highlights @Agenusbio TIGIT(s). Why the excitement? What are optimal combos? Learn more about our novel TIGIT programs with superior pre-clinical tumor killing as monotherapy in PD-1 combo. #TIGIT #Immunotherapy agenusbio.com/wp-content/upl…